November 11th, 22
Social Survey Research Information Co., Ltd.
Social Survey Research Information Co., Ltd.
NEWS
PatientsMap 2022 Japan version now available
Rare diseases, for which there are few physicians to treat them, and intractable cancers are among those at the top in terms of needs for new drugs.
Ophthalmologic diseases are more common among office-based practitioners (facilities with 99 or fewer beds).
Social Survey Research Information Co., Ltd. and M3, Inc. launched the Japan version of PatientsMap 2022 on September 30, 2022.
New drug needs were analyzed by the number of beds.
We looked at physicians' needs for new drugs for the 10 diseases with the highest desire rates based on physicians who treat each disease, by the number of beds, i.e., physicians at facilities with 100 or more beds and at facilities with 99 or fewer beds.
(Table 1) shows diseases for which there are strong needs for new drugs at facilities that have at least 100 beds. The top-ranked diseases are "lymphangiomatosis," "giant lymphatic malformation," and "leiomyosarcoma," which are rare diseases and less than 1% of physicians treat them, as well as "bile duct cancer" and "pancreatic cancer," both of which are considered to have a poor prognosis.
(Table 2) looks at facilities with 99 or fewer beds in a similar way. As with those with 100 or more beds, rare diseases dominated the top of the list, but cancer was not among the top 10 diseases. Four of these top 10 diseases were ophthalmologic diseases.
As such, it was found that the needs for new drugs differs depending on the number of beds the facility has.
(Table 1) Diseases for which there are strong needs for new drugs:
Facilities with 100 or more beds Number of responses: 14,813
Facilities with 100 or more beds Number of responses: 14,813
| Disease name | % of Physicians' managing the condition | % of Physicians' needs for new drugs |
|---|---|---|
| Lymphangiomatosis/Gorham-Stout disease | 0.1% | 73% |
| Giant lymphatic malformation (cervicofacial lesion) | 0.1% | 64% |
| Chronic nonspecific multiple ulcers of the small intestine | 0.0% | 64% |
| Leiomyosarcoma | 0.6% | 63% |
| Dominant dystrophic epidermolysis bullosa | 0.0% | 60% |
| Treatment resistant schizophrenia | 3.4% | 59% |
| Bile duct carcinoma | 3.3% | 58% |
| Inclusion body myositis | 0.7% | 57% |
| Retinitis pigmentosa | 0.4% | 55% |
| Pancreatic cancer | 5.6% | 55% |
(Table 2) Diseases for which there are strong needs for new drugs:
Facilities with 99 beds or fewer Number of responses: 5,406
Facilities with 99 beds or fewer Number of responses: 5,406
| Disease name | % of Physicians' managing the condition | % of Physicians' needs for new drugs |
|---|---|---|
| Retinitis pigmentosa | 1.9% | 82% |
| Recessive dystrophic epidermolysis bullosa | 0.1% | 67% |
| Diabetic macular edema | 6.1% | 64% |
| Dravet syndrome | 0.3% | 53% |
| Central retinal vein occlusion (CRVO) | 4.1% | 52% |
| Specifically; Exudative age-related macular degeneration | 5.9% | 52% |
| Gambling addiction | 0.9% | 50% |
| Mucopolysaccharidosis type IV (Morquio syndrome) | 0.0% | 50% |
| Pompe Disease | 0.1% | 50% |
| Hereditary autoinflammatory syndrome | 0.1% | 50% |
What is PatientsMap?
PatientsMap is a large database that surveys, with the cooperation of physicians, about 400 diseases in terms of physician coverage, number of patients, unmet medical needs (diseases for which new drugs are desired, reasons for wanting new drugs, and percentage of patients for whom administering new drugs would be considered), and the activities of real sales reps (in-person) and e-detailing activities of pharmaceutical companies. The same survey frame has been used continuously for more than 10 years since 2010.
Overview of PatientsMap 2022 Japan Version (2022JP)
A survey was conducted of m3 panel physicians.| Target respondents: | : | M3-registered physicians |
|---|---|---|
| Method | : | Online survey |
| Fieldwork period | : | May 10 to September 5, 2022 |
| Sample size collected | : | 20,219 sample |
| Number of conditions surveyed | : | 437 diseases |
| Survey item: | : | Total number of patients (in the past month) Number of patients seen by condition (in the past month) Number of patients who were prescribed drugs by condition (in the past month) Need for new therapy Percentage of patients for whom administering new drugs would be considered Reasons why new drugs are desired by condition Manufacturers that have visited (in the past month) Manufacturers that you have had a remote meeting with one of their sales reps (in the past month) Manufacturer that have provided you with information via the Internet (in the past month) Reliable manufacturers |
Contact Information
| Social Survey Research Information Co., Ltd. | ||
|---|---|---|
| : | patientsmap@ssri.com | |
Social Survey Research Information Co., Ltd.
| Established | April 1982 |
| Capital | 27 million JPY |
| President & CEO | Takashi Makita |
| Number of employees | 137 |
| Location | Head Office NMF Shinjuku East Bldg. 2F, 3F 10-5 Tomihisacho, Shinjuku-ku, Tokyo 162-0067 JAPAN |
| Osaka office Daimei Bldg. 4F, 4-6-3 Hirano-cho, Chuo-ku, Osaka 541-0046 JAPAN | |
| Affiliate companies | PD Research Co., Ltd. MDB Co. SSRI China Co., Ltd. (overseas subsidiary) SSRI Asia Pacific Co., Ltd. (overseas subsidiary) HIMA Research (overseas affiliate) |
| URL | https://www.ssri.com/ |
M3, Inc.
| Established | September 2000 |
| Capital | 29.129 billion JPY (as of March 31, 2022) |
| Representative Director | Itaru Tanimura |
| Number of employees, consolidated | 9,384 (as of March 31, 2022) |
| Location | Akasaka Intercity 10F 1-11-44 Akasaka, Minato-ku, Tokyo |
| URL | https://corporate.m3.com/ |